Affinage

TTF2

Transcription termination factor 2 · UniProt Q9UNY4

Length
1162 aa
Mass
129.6 kDa
Annotated
2026-04-28
20 papers in source corpus 12 papers cited in narrative 14 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TTF2 is a multifunctional protein that operates both as a forkhead-domain transcription factor governing thyroid and craniofacial development and as an SNF2-family ATPase that orchestrates mitotic chromosome clearance and replisome disassembly. As the transcription factor FOXE1, TTF2 binds thyroglobulin and thyroperoxidase promoters, represses TTF-1 and Pax-8 through a DNA-binding-independent repressor domain, and cooperates with CTF/NF1 to mediate TSH/insulin-regulated thyroid gene expression; loss-of-function forkhead-domain mutations cause thyroid agenesis with cleft palate and choanal atresia (Bamforth-Lazarus syndrome) (PMID:9214635, PMID:9697705, PMID:10329730, PMID:10944465). As an ATPase, TTF2 evicts RNA polymerase II from mitotic chromosomes in an ATPase-dependent manner and, through a separable ATPase-independent mechanism, bridges phosphorylated TRAIP to DNA polymerase ε via N-terminal zinc fingers and an NPF-POLE2 interaction, thereby promoting CMG helicase ubiquitylation and replisome disassembly at stalled mitotic replication forks (PMID:15467445, PMID:39651145). TTF2 protein levels oscillate during the cell cycle, peaking in S/G2/M and declining in late mitosis through APC/C-CDH1-mediated degradation; TTF2 also binds CDC20 to suppress premature Mitotic Checkpoint Complex formation, coupling its own turnover to spindle checkpoint regulation (PMID:40410652).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 1997 High

    Cloning of TTF-2 established it as a forkhead-domain transcription factor that binds Tg and TPO promoter elements and whose transient developmental downregulation suggested a role as a negative regulator of thyroid differentiation genes.

    Evidence cDNA cloning, DNA binding assays, and in situ hybridization in mouse embryos

    PMID:9214635

    Open questions at the time
    • Mechanism of transcriptional repression was undefined
    • No in vivo loss-of-function data in animal models
    • Upstream signals controlling TTF-2 expression in vivo were unknown
  2. 1997 High

    TTF-2 mRNA was shown to be transcriptionally upregulated by TSH (via cAMP), insulin, and IGF-I in thyroid cells, placing TTF-2 downstream of hormonal signaling cascades that control thyroid function.

    Evidence Northern blot, nuclear run-off assays, and pharmacological stimulation in FRTL-5 rat thyroid cells

    PMID:9287345

    Open questions at the time
    • Whether hormonal regulation occurs in vivo was not tested
    • Transcription factor cascades upstream of TTF-2 promoter were not identified
  3. 1998 High

    Discovery of a homozygous forkhead-domain missense mutation (A65V) that abolishes DNA binding and transcriptional activity established TTF-2 loss-of-function as the genetic cause of Bamforth-Lazarus syndrome (thyroid agenesis, cleft palate, choanal atresia).

    Evidence Homozygosity mapping, Sanger sequencing, DNA binding and reporter assays with mutant protein in a consanguineous pedigree

    PMID:9697705

    Open questions at the time
    • Mouse knockout phenotype had not yet been characterized
    • Whether partial loss-of-function alleles cause milder thyroid disease was unknown
  4. 1999 High

    Physical interaction between TTF-2 and CTF/NF1 was demonstrated, and spacing between their cognate DNA sites was shown to be critical for TPO promoter activity, revealing a cooperative mechanism for hormonal gene regulation.

    Evidence GST pull-down, transfection reporter assays, and promoter spacing mutagenesis

    PMID:10329730

    Open questions at the time
    • Structural basis of the TTF-2–CTF/NF1 interaction was not resolved
    • Whether this interaction occurs on chromatin in vivo was not shown
  5. 2000 Medium

    Mapping of a minimal repressor domain showed that TTF-2 inhibits TTF-1 and Pax-8 transcriptional activity in a DNA-binding-independent manner, suggesting cofactor sequestration as the mechanism of repression.

    Evidence Deletion mutagenesis and transcriptional reporter assays

    PMID:10944465

    Open questions at the time
    • The identity of the sequestered cofactor was not determined
    • Repressor activity was demonstrated only in reporter assays, not on endogenous genes
  6. 2004 High

    The ATPase function of TTF2 (hLodestar) was functionally separated from its transcription-factor role when siRNA knockdown revealed that TTF2 is required for eviction of RNA polymerase II from mitotic chromosomes, with rescue by an siRNA-resistant construct confirming on-target activity.

    Evidence siRNA knockdown, rescue with siRNA-resistant GFP-TTF2, fluorescence microscopy of mitotic chromosomes

    PMID:15467445

    Open questions at the time
    • Whether ATPase catalytic activity was directly required was not formally tested with catalytic-dead mutants
    • Substrates or cofactors for RNAPII eviction were not identified
  7. 2024 High

    Biochemical reconstitution revealed a second, ATPase-independent mitotic role for TTF2: N-terminal zinc fingers bind CDK1-phosphorylated TRAIP while a separate NPF motif contacts POLE2, forming a TRAIP–TTF2–Polε bridge that promotes CMG ubiquitylation and replisome disassembly at stalled mitotic forks.

    Evidence Xenopus egg extract reconstitution, domain mutagenesis, CDK1 phosphorylation and ubiquitylation assays, with convergent results from two independent preprints

    PMID:39651145

    Open questions at the time
    • Mechanism has not been validated in mammalian cells
    • How TTF2 is recruited specifically to stalled versus active forks is unclear
    • Structural details of the ternary TRAIP–TTF2–Polε complex are lacking
  8. 2025 Medium

    TTF2 was found to oscillate during the cell cycle under APC/C-CDH1 control, and to bind CDC20 to prevent premature Mitotic Checkpoint Complex assembly — linking TTF2 degradation to spindle checkpoint activation upon persistent mitotic arrest.

    Evidence Co-immunoprecipitation, ubiquitination assays, siRNA knockdown, overexpression, and flow cytometry in human cell lines

    PMID:40410652

    Open questions at the time
    • The CDC20-binding interface on TTF2 has not been structurally defined
    • Whether this checkpoint role is conserved across species is unknown
    • Relationship between the CDC20 binding and TRAIP-bridging functions during mitosis is unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unknown how TTF2's two fundamentally distinct biochemical activities — forkhead transcription factor and SNF2 ATPase/scaffold — are coordinated in vivo, and whether the transcription-factor and replisome-disassembly functions are ever co-deployed in the same cell type.
  • No structural model of full-length TTF2 exists
  • Cell-type-specific deployment of the dual activities has not been systematically characterized
  • Whether TTF2 forkhead and ATPase activities are encoded by the same or different gene products in all species has not been formally resolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003677 DNA binding 4 GO:0140110 transcription regulator activity 3 GO:0060090 molecular adaptor activity 2 GO:0140657 ATP-dependent activity 2 GO:0098772 molecular function regulator activity 1
Localization
GO:0005634 nucleus 2 GO:0005694 chromosome 2
Pathway
R-HSA-1266738 Developmental Biology 3 R-HSA-1640170 Cell Cycle 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-69306 DNA Replication 2
Partners
CDC20CDC5LCDH1CTF/NF1POLE2TRAIP

Evidence

Reading pass · 14 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1997 TTF-2 (FOXE1) is a forkhead domain-containing transcription factor that binds DNA sites on both thyroglobulin (Tg) and thyroperoxidase (TPO) promoters, and its expression is transiently downregulated in the developing thyroid just before onset of Tg and TPO gene expression, suggesting a role as a negative controller of thyroid-specific gene expression during development. cDNA cloning, DNA binding assays, in situ hybridization/expression analysis in mouse embryos The EMBO journal High 9214635
1997 TTF-2 mRNA levels are regulated by TSH, insulin, and IGF-I in FRTL-5 thyroid cells; TSH acts via cAMP (mimicked by forskolin), the effects are additive with insulin, and the increase in mRNA is accompanied by increased transcription rate as shown by run-off assays, requiring ongoing protein synthesis. Northern blot, nuclear run-off transcription assay, pharmacological stimulation in FRTL-5 cells The Journal of biological chemistry High 9287345
1998 A missense mutation (Ala65Val) within the forkhead domain of TTF-2/FKHL15 (the human homologue of mouse TTF-2) causes impaired DNA binding and loss of transcriptional function, establishing loss-of-function as the cause of thyroid agenesis, cleft palate, and choanal atresia. Homozygosity mapping, Sanger sequencing, DNA binding assays, transcriptional reporter assays with mutant protein Nature genetics High 9697705
1999 TTF-2 physically interacts with CTF/NF1 proteins (demonstrated by GST pull-down), and this interaction is required for efficient hormonal (TSH/insulin/cAMP) regulation of the thyroperoxidase gene; CTF/NF1-C is itself hormonally regulated, and spacing between TTF-2 and CTF/NF1 binding sites is critical for promoter activity. GST pull-down, transfection reporter assays, protein-DNA interaction studies, site-directed mutagenesis of promoter spacing The Journal of biological chemistry High 10329730
2000 TTF-2 acts as a promoter-specific transcriptional repressor that inhibits TTF-1 and Pax-8 activity in a DNA-binding-independent manner; a minimal repressor domain was identified that functions as an independent domain and likely interferes with a specific cofactor required for TTF-1 and Pax-8 activity. Transcriptional reporter assays, deletion mutagenesis to define minimal repressor domain, DNA binding assays Biochemical and biophysical research communications Medium 10944465
2002 A second human TTF-2 missense mutation (S57N) within the forkhead DNA binding domain causes impaired DNA binding and partial loss of transcriptional function, confirming that the forkhead domain is essential for DNA binding and transactivation. Sanger sequencing, DNA binding assays, transcriptional reporter assays with mutant protein Human molecular genetics High 12165566
2003 Human TTF2 (hLodestar/HuF2), a SNF2 family ATPase, interacts with the pre-mRNA splicing factor CDC5L as shown by yeast two-hybrid and co-immunoprecipitation from HeLa nuclear extracts; a truncated TTF2 polypeptide overlapping the CDC5L-binding region inhibits pre-mRNA splicing by disrupting spliceosome assembly, implicating TTF2 in the splicing pathway. Yeast two-hybrid, co-immunoprecipitation from HeLa nuclear extract, in vitro splicing inhibition assay with truncated polypeptide Biochemical and biophysical research communications Medium 12927788
2004 TTF2 is an RNA polymerase II termination factor responsible for mitotic repression of transcription elongation; siRNA-mediated knockdown of TTF2 causes retention of RNA polymerase II on condensed mitotic chromosomes, and this phenotype is rescued by an siRNA-resistant GFP-TTF2 replacement vector, proving TTF2 is directly responsible. siRNA knockdown, rescue with siRNA-resistant replacement vector expressing GFP-tagged TTF2, fluorescence microscopy of mitotic chromosomes Cell cycle (Georgetown, Tex.) High 15467445
2006 A third TTF-2 missense mutation (R102C) within the forkhead DNA binding domain abolishes DNA binding and transcriptional activity, confirming that arginine 102 is critical for forkhead domain function. Sanger sequencing, DNA binding assays, transcriptional reporter assays with mutant protein The Journal of clinical endocrinology and metabolism Medium 16882747
2012 Overexpression of mouse TTF-2 in transgenic mice (driven by the ROSA26 promoter) causes cleft palate, with TTF-2 highly expressed in the medial edge epithelium (MEE) from E12.5 to E14.5, demonstrating that precise TTF-2 dosage is required for normal palatogenesis. Transgenic mouse overexpression model, immunohistochemistry for localization in MEE, phenotypic analysis Journal of cellular and molecular medicine Medium 22304410
2024 TTF2, a SWI/SNF ATPase, promotes replisome disassembly at stalled mitotic forks via two distinct mechanisms: (1) an N-terminal zinc finger binds phosphorylated TRAIP (phosphorylated by Cyclin B-CDK1) and an adjacent TTF2 peptide contacts the CMG-associated leading strand DNA polymerase ε, forming a TRAIP-TTF2-Polε bridge that promotes CMG ubiquitylation and unloading independently of TTF2 ATPase activity; (2) RNAPII eviction from mitotic chromosomes requires TTF2 ATPase activity. Xenopus egg extract reconstitution, co-immunoprecipitation, domain mapping/mutagenesis, CDK1 phosphorylation assays, ubiquitylation assays, fluorescence microscopy bioRxivpreprint High 39651145
2024 Independent confirmation that TTF2 couples TRAIP to DNA Polymerase ε (Polε) during mitosis: tandem zinc fingers at the TTF2 amino terminus recognize phosphorylated TRAIP, and a separate motif binds POLE2, enabling TRAIP to ubiquitylate the CMG helicase and trigger replisome disassembly and Mitotic DNA Synthesis (MiDAS); this activity is distinct from TTF2 ATPase-dependent RNAPII eviction. Biochemical reconstitution, co-immunoprecipitation, domain mutagenesis (zinc fingers, POLE2-binding motif), ubiquitylation assays bioRxivpreprint High
2025 TTF2 protein levels oscillate during the cell cycle (high in S/G2/M, low in late mitosis/G1); TTF2 is ubiquitinated and degraded by APC/C-CDH1; TTF2 binds CDC20 and prevents Mitotic Checkpoint Complex (MCC) formation during normal mitosis, but upon persistent G2/M arrest TTF2 is degraded by APC/C-CDH1, releasing CDC20 to promote MCC assembly; TTF2 knockdown causes G2/M arrest while overexpression accelerates M/G1 transition. Co-immunoprecipitation, ubiquitination assays, siRNA knockdown, overexpression, flow cytometry cell cycle analysis, proteasome inhibition Science China. Life sciences Medium 40410652
2025 TTF2 contains an NPF motif that binds to the POLE2 subunit of DNA polymerase ε with micromolar affinity; mutation of the TTF2 NPF motif abolishes binding in cell extracts, identifying POLE2 as a direct binding partner of TTF2 via short linear motif recognition. Native holdup quantitative binding assay, mutational analysis of NPF motif, affinity screens in cell extracts, AlphaFold structural predictions bioRxivpreprint Medium

Source papers

Stage 0 corpus · 20 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1998 Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. Nature genetics 301 9697705
1997 TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation. The EMBO journal 219 9214635
2007 Diagnostic utility of thyroid transcription factors Pax8 and TTF-2 (FoxE1) in thyroid epithelial neoplasms. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 204 18084247
2002 A novel loss-of-function mutation in TTF-2 is associated with congenital hypothyroidism, thyroid agenesis and cleft palate. Human molecular genetics 114 12165566
1997 Transcriptional control of the forkhead thyroid transcription factor TTF-2 by thyrotropin, insulin, and insulin-like growth factor I. The Journal of biological chemistry 64 9287345
2013 Contribution of ATM and FOXE1 (TTF2) to risk of papillary thyroid carcinoma in Belarusian children exposed to radiation. International journal of cancer 52 24105688
2000 The thyroid transcription factor 2 (TTF-2) is a promoter-specific DNA-binding independent transcriptional repressor. Biochemical and biophysical research communications 50 10944465
2006 A novel missense mutation in human TTF-2 (FKHL15) gene associated with congenital hypothyroidism but not athyreosis. The Journal of clinical endocrinology and metabolism 45 16882747
1999 The interaction between the forkhead thyroid transcription factor TTF-2 and the constitutive factor CTF/NF-1 is required for efficient hormonal regulation of the thyroperoxidase gene transcription. The Journal of biological chemistry 42 10329730
2010 Spectrum of Human Foxe1/TTF2 Mutations. Hormone research in paediatrics 41 20453517
2004 Genetic analysis of TTF-2 gene in children with congenital hypothyroidism and cleft palate, congenital hypothyroidism, or isolated cleft palate. Thyroid : official journal of the American Thyroid Association 19 15320969
2004 Rescue of the TTF2 knockdown phenotype with an siRNA-resistant replacement vector. Cell cycle (Georgetown, Tex.) 15 15467445
2003 hLodestar/HuF2 interacts with CDC5L and is involved in pre-mRNA splicing. Biochemical and biophysical research communications 14 12927788
2012 Overexpression of mouse TTF-2 gene causes cleft palate. Journal of cellular and molecular medicine 11 22304410
2004 TTF-2 stimulates expression of 17 genes, including one novel thyroid-specific gene which might be involved in thyroid development. Molecular and cellular endocrinology 10 15223130
2015 Replication and Meta-Analysis of Common Gene Mutations in TTF1 and TTF2 with Papillary Thyroid Cancer. Medicine 9 26356687
1998 TTF-2 does not appear to be a key mediator of the effect of cyclic AMP on thyroglobulin gene transcription in primary cultured dog thyrocytes. Biochemical and biophysical research communications 8 9446794
2024 TTF2 promotes replisome eviction from stalled forks in mitosis. bioRxiv : the preprint server for biology 6 39651145
2025 Mutual regulation between cell cycle and transcription termination factor TTF2. Science China. Life sciences 1 40410652
2012 Molecular Analysis of TTF-1 and TTF-2 Genes in Patients with Early Onset Papillary Thyroid Carcinoma. Journal of oncology 0 22481925